Shanghai Hile Bio-tech (603718) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Hile Bio-tech (603718) has a cash flow conversion efficiency ratio of -0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-1.18 Million ≈ $-173.40K USD) by net assets (CN¥1.70 Billion ≈ $248.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shanghai Hile Bio-tech - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Shanghai Hile Bio-tech's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Shanghai Hile Bio-tech debt and liabilities for a breakdown of total debt and financial obligations.
Shanghai Hile Bio-tech Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Hile Bio-tech ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
63 moons technologies limited
NSE:63MOONS
|
-0.037x |
|
Samkang M&T Co.Ltd
KQ:100090
|
0.132x |
|
American Integrity Insurance Group, Inc.
NYSE:AII
|
0.149x |
|
Power Wind Health Industry Incorporated
TW:8462
|
0.239x |
|
Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares
NASDAQ:ANSC
|
N/A |
|
GRM Overseas Limited
NSE:GRMOVER
|
0.004x |
|
Hangzhou Landscape Architecture Design Institute Co Ltd
SHE:300649
|
0.012x |
|
Advanced Ceramic X
TWO:3152
|
0.017x |
Annual Cash Flow Conversion Efficiency for Shanghai Hile Bio-tech (2011–2024)
The table below shows the annual cash flow conversion efficiency of Shanghai Hile Bio-tech from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Shanghai Hile Bio-tech worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.70 Billion ≈ $249.23 Million |
CN¥46.47 Million ≈ $6.80 Million |
0.027x | +1190.98% |
| 2023-12-31 | CN¥1.17 Billion ≈ $171.91 Million |
CN¥-2.94 Million ≈ $-429.95K |
-0.003x | -100.95% |
| 2022-12-31 | CN¥1.11 Billion ≈ $162.57 Million |
CN¥292.91 Million ≈ $42.86 Million |
0.264x | +496.48% |
| 2021-12-31 | CN¥987.19 Million ≈ $144.46 Million |
CN¥43.63 Million ≈ $6.38 Million |
0.044x | -74.64% |
| 2020-12-31 | CN¥962.20 Million ≈ $140.80 Million |
CN¥167.68 Million ≈ $24.54 Million |
0.174x | +191.93% |
| 2019-12-31 | CN¥992.57 Million ≈ $145.24 Million |
CN¥59.25 Million ≈ $8.67 Million |
0.060x | +223.68% |
| 2018-12-31 | CN¥1.03 Billion ≈ $150.10 Million |
CN¥18.92 Million ≈ $2.77 Million |
0.018x | -43.23% |
| 2017-12-31 | CN¥1.07 Billion ≈ $157.29 Million |
CN¥34.92 Million ≈ $5.11 Million |
0.032x | -69.87% |
| 2016-12-31 | CN¥1.01 Billion ≈ $147.11 Million |
CN¥108.39 Million ≈ $15.86 Million |
0.108x | -48.51% |
| 2015-12-31 | CN¥963.31 Million ≈ $140.96 Million |
CN¥201.69 Million ≈ $29.51 Million |
0.209x | +6.09% |
| 2014-12-31 | CN¥558.50 Million ≈ $81.73 Million |
CN¥110.22 Million ≈ $16.13 Million |
0.197x | -33.07% |
| 2013-12-31 | CN¥500.66 Million ≈ $73.26 Million |
CN¥147.63 Million ≈ $21.60 Million |
0.295x | +12.64% |
| 2012-12-31 | CN¥467.89 Million ≈ $68.47 Million |
CN¥122.48 Million ≈ $17.92 Million |
0.262x | -29.01% |
| 2011-12-31 | CN¥405.74 Million ≈ $59.37 Million |
CN¥149.61 Million ≈ $21.89 Million |
0.369x | -- |
About Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry… Read more